Combination therapy in hormone-refractory prostate cancer

被引：0
作者：
Daniel P. Petrylak
机构：
来源：
Current Oncology Reports | 2001年 / 3卷 / 5期
关键词：
Prostate Cancer; Hydrocortisone; Docetaxel; Mitoxantrone; Estramustine;
D O I：
10.1007/s11912-001-0033-4
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：453 / 453
相关论文
共 50 条
  • [31] A weekly schedule of docetaxel for metastatic hormone-refractory prostate cancer
    Ferrero, JM
    Foa, C
    Thezenas, S
    Ronchin, P
    Peyrade, F
    Valenza, B
    Lesbats, G
    Garnier, G
    Boublil, JL
    Tchiknavorian, X
    Chevallier, D
    Amiel, J
    ONCOLOGY, 2004, 66 (04) : 281 - 287
  • [32] Combination of Bevacizumab and Docetaxel in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer: A Phase 2 Study
    Di Lorenzo, Giuseppe
    Figg, William D.
    Fossa, Sophie D.
    Mirone, Vincenzo
    Autorino, Riccardo
    Longo, Nicola
    Imbimbo, Ciro
    Perdona, Sisto
    Giordano, Antonio
    Giuliano, Mario
    Labianca, Roberto
    De Placido, Sabino
    EUROPEAN UROLOGY, 2008, 54 (05) : 1089 - 1096
  • [33] Retrospective Analysis of an Oral Combination of Dexamethasone, Uracil plus Tegafur and Cyclophosphamide for Hormone-refractory Prostate Cancer
    Hatano, Koji
    Nonomura, Norio
    Nishimura, Kazuo
    Kawashima, Atsunari
    Mukai, Masatoshi
    Nagahara, Akira
    Nakai, Yasutomo
    Nakayama, Masashi
    Takayama, Hitoshi
    Tsujimura, Akira
    Okuyama, Akihiko
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2011, 41 (02) : 253 - 259
  • [34] Phase II trial evaluating a docetaxel-capecitabine combination as treatment for hormone-refractory prostate cancer
    Ferrero, Jean-Marc
    Chamorey, Emmanuel
    Oudard, Stephane
    Dides, Sabine
    Lesbats, Gerard
    Cavaglione, Gerard
    Nouyrigat, Pierre
    Foa, Cyril
    Kaphan, Regis
    CANCER, 2006, 107 (04) : 738 - 745
  • [35] Oral combination of cyclophosphamide, uracil plus tegafur and estramustine for hormone-refractory prostate cancer
    Nishimura, K
    Nonomura, N
    Ono, Y
    Nozawa, M
    Fukui, T
    Harada, Y
    Imazu, T
    Takaha, N
    Sugao, H
    Miki, T
    Okuyama, A
    ONCOLOGY, 2001, 60 (01) : 49 - 54
  • [36] Combination chemotherapy with weekly paclitaxel or docetaxel, carboplatin, and estramustine for hormone-refractory prostate cancer
    Yasufuku, Tomihiko
    Shigemura, Katsumi
    Matsumoto, Osamu
    Arakawa, Soichi
    Fujisawa, Masato
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2010, 16 (03) : 200 - 205
  • [37] Predictive modelling in hormone-refractory prostate cancer (HRPC)
    Bellmunt, Joaquim
    Carles, Joan
    Albanell, Joan
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2009, 11 (02) : 82 - 85
  • [38] Does the addition of vinorelbine to hormone therapy prolong survival of men with hormone-refractory prostate cancer?
    Pummer, K
    NATURE CLINICAL PRACTICE UROLOGY, 2005, 2 (02): : 80 - 81
  • [39] Update in the management of patients with hormone-refractory prostate cancer
    Moore, CN
    George, DJ
    CURRENT OPINION IN UROLOGY, 2005, 15 (03) : 157 - 162
  • [40] Predictive modelling in hormone-refractory prostate cancer (HRPC)
    Joaquim Bellmunt
    Joan Carles
    Joan Albanell
    Clinical and Translational Oncology, 2009, 11 : 82 - 85
12345